基本信息
views: 571
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Professor Coiffier’s special interest has always been to improve treatment outcomes in aggressive lymphoma. He initiated studies to highlight the benefits of the ACVBP (adriamycin-cyclophosphamide-vindesine-bleomycin-prednisone) regimen in aggressive lymphomas. Professor Coiffier was the first to describe the synergy of the anti-CD20 antibody rituximab with the CHOP (cyclophosphamide-doxorubicin-vincristine-prednisone) regimen in diffuse large cell lymphoma in a landmark study published in the New England Journal of Medicine in 20021. Furthermore, he played an instrumental role in many drug approvals worldwide, helping to establish novel treatment options for patients with lymphoma and has published over 400 papers in peer-reviewed journals.
Research Interests
Papers共 727 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Innovative Leukemia and Lymphoma Therapypp.125-147, (2019)
Qian Shi, Norbert Schmitz,Fang-Shu Ou,Jesse G Dixon,David Cunningham,Michael Pfreundschuh,John F Seymour,Ulrich Jaeger,Thomas M Habermann,Corinne Haioun,Hervé Tilly, Hervé Ghesquieres,
Lauriane Filliatre-Clement, Delphine Maucort-Boulch,Estelle Bourbon,Lionel Karlin,Violaine Safar, Emmanuel Bachy,Pierre Sesques,Emmanuelle Ferrant,Fadela Bouafia,Anne Lazareth,Dana Ghergus,Bertrand Coiffier,
The Lancet. Haematologyno. 11 (2018): e543-e553
The Lancet. Haematologyno. 8 (2018): e359-e367
Journal of clinical oncology : official journal of the American Society of Clinical Oncologyno. 9 (2018): 923-923
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn